Anticoagulants, Oral and SQ

• Anticoagulants - Feb 04, 2021
• Anticoagulants - Nov 21, 2019
• Anticoagulants Literature Scan - May 25, 2017

• Direct-acting Anticoagulants - Jul 28, 2016
• Anticoagulants - May 28, 2015
• Anticoagulant Class Update - Jul 31, 2014
• Abbreviated Class Update: Anticoagulants - Mar 28, 2013
• Class Review: Oral Anticoagulants - Jan 26, 2012

• Duplicate Therapy Drug Evaluation - Dec 01, 2022
• Non-Vitamin K Oral Anticoagulants Policy Evaluation - May 25, 2017
• Direct-acting Oral Anticoagulants - May 28, 2015

• November 2017 - Marketing Claims of Newer Drugs and the Evidence
• August 2017 - Oral Anticoagulant Update
• October 2015 - From Antidotes to Edoxaban: An Oral Anticoagulation Update

• October 2014 - What's New with Oral Anticoagulants?
• November 2013 - Update on the New Oral Anticoagulants with a Focus on Apixaban

Y = preferred
N = non-preferred. Non-preferred drugs listed as N but without clinical drug use criteria are subject to the Non-Preferred Drugs in Select PDL Classes prior authorization criteria. New drugs will be listed as N until reviewed by the P&T Committee and are subject to the New Drug Policy.
V = voluntary non-preferred. Non-preferred mental health drugs are listed as V and prior authorization is not required.
Null (i.e. blank) = indicates the class or specific drug has not been reviewed for PDL placement.